FDA Approves RAMIPRIL — Rising Pharma Holdings, Inc.

Rising Pharma Holdings, Inc. received FDA approval on June 8, 2011, for its ANDA091604 application to market the generic version of RAMIPRIL, an oral antihypertensive. This approval is expected to expand the company’s product portfolio in the cardiovascular therapeutics sector and allow it to compete directly with the branded market leader.